Cellectar Biosciences (CLRB) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Lantern Pharma (LTRN) over the past year, losing 70.7% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -99.5% for CLRB. Cellectar Biosciences is the larger company by market cap ($13.3 million vs $12.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | LTRN |
|---|---|---|
| Share price | $1.41 | $0.8301 |
| Market cap | $13.33M | $12.40M |
| 1-day change | +0.71% | +0.01% |
| YTD return | -52.54% | -72.61% |
| 1-year return | -70.71% | -81.92% |
| 5-year return | -99.49% | -91.71% |
| EPS (TTM) | $-3.46 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $4.68 |
| 52-week low | $1.34 | $0.83 |
| Distance from 52-week high | -72.19% | -82.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +715.60% | +2008.18% |
| Average volume | 63.86K | 180.42K |
| Shares outstanding | 9.45M | 14.94M |
| Employees | 11 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed LTRN by 11.2 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
CLRB vs LTRN FAQ
Which is bigger, Cellectar Biosciences or Lantern Pharma?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.33M compared with $12.40M for Lantern Pharma (LTRN).
Which stock has performed better over the past year, CLRB or LTRN?
CLRB returned -70.71% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.